Search review questions

Risk of recurrence and mean time‐to‐recurrence after induction of remission at 2 or 6 months · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

Mean change from baseline in logMAR visual acuity at 6 months*2 · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

Mean change from baseline in number of topical or systemic steroids at 6 months*2 · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

Frequency and nature of adverse effects · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old

Risk of any ocular infection within 1 month following corneal abrasion · children and adults with corneal abrasion

Time to clinical cure, defined as complete healing (re‐epithelialization) of the epithelium · children and adults with corneal abrasion

Change in pain intensity from baseline to 1 month · children and adults with corneal abrasion

Recurrent corneal erosion within 1 year · children and adults with corneal abrasion

Change in visual acuity from baseline to 1 year, or loss of 1 or more lines of best‐corrected visual acuity at 1 month · children and adults with corneal abrasion

Quality of life at 1 month · children and adults with corneal abrasion

Adverse effects · children and adults with corneal abrasion

Proportion of participants achieving control of inflammation (higher number of events is better) · NIIPPU

Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU

Proportion of participants achieving steroid‐sparing control§ (higher number of events is better) · NIIPPU

Proportion of participants experiencing complications or requiring cessation of medication (lower number of events is better) · NIIPPU

Proportion of participants achieving control of inflammation (higher number of events is better) · NIIPPU

Change in BCVA (lower logMAR indicate better vision) · NIIPPU

Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU

Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU

Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU

Proportion of participants experiencing complications or requiring cessation of medication (lower number of events is better) · NIIPPU

Change in BCVA (lower logMAR indicate better vision) · NIIPPU

Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) Â · NIIPPU

Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU

Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU

Proportion of participants experiencing complications or requiring cessation of medication (lower number of events is better) · NIIPPU

Proportion of participants achieving control of inflammation§ (higher number of events is better) · NIIPPU

Change in BCVA (lower logMAR indicate better vision) · NIIPPU

Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU

Change in patient‐reported symptom scores (lower is favored) · people with dry eye

Change in TBUT (seconds) (longer is favored) · people with dry eye

Change in fluorescein corneal staining scores (lower is favored) · people with dry eye

Change in tear osmolarity (mOsm/kg) (lower is favored) · people with dry eye

Adverse effect: incident elevated IOP ( · people with dry eye

Adverse effect: new cataract formation · people with dry eye

Change in patient‐reported quality of life scores · people with dry eye

Change in TBUT (seconds) (longer is favored) · people with dry eye

Change in fluorescein corneal staining scores (lower is favored) · people with dry eye

Change in tear osmolarity (mOsm/kg) (lower is favored) · people with dry eye

Adverse effect: incident elevated IOP ( · people with dry eye

Adverse effect: new cataract formation ( · people with dry eye

Change in patient‐reported symptom scores (lower is favored) · people with dry eye

Change in patient‐reported quality of life scores · people with dry eye

Motor alignment at near Change in exotropia control at near fixation, measured from baseline to 3 years using the prism and alternate cover test · people with intermittent exotropia, aged 3 to < 11 years

Stereoacuity at distance Loss of ≥ 2 octaves near stereoacuity, measured using the Preschool Randot test 3 years after surgery · people with intermittent exotropia, aged less than 11 years

Motor alignment at distance fixation Measured using PACT at 6 months · people with intermittent exotropia, aged less than 11 years

Motor fusion test · people with intermittent exotropia, aged less than 11 years

Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged less than 11 years

Quality of life measures Measured at 3 years using the IXTQ scores for children, parents, or parent proxies (i.e. parents' perception of their children's quality of life). Scores could range from 0 (worst quality of life) to 100 (best quality of l... · people with intermittent exotropia, aged less than 11 years

Motor alignment at near fixation Measured using PACT at 6 months · people with intermittent exotropia, aged 5 to 49 years